title: Antitumor efficacy of viral therapy using genetically engineered Newcastle disease virus [NDV(F3aa)-GFP] for peritoneally disseminated gastric cancer.
abstract: Peritoneal dissemination is a common and fatal clinical manifestation of gastric cancer with few effective therapies available. Natural Newcastle disease virus (NDV) has been shown to be an effective oncolytic agent, and recent advances now allow genetic manipulation of this virus to improve cancer killing and safety. This study was designed to investigate the effectiveness of a genetically engineered NDV in the treatment of peritoneally disseminated gastric carcinoma. NDV mutant virus containing a modified F cleavage site and insertion of enhanced green fluorescent protein (GFP), NDV(F3aa)-GFP, was tested in vitro against human gastric cancer cells by standard cytotoxicity at different multiplicities of infection. To test NDV(F3aa)-GFP in vivo in a peritoneal carcinomatosis gastric tumor model, MKN-74 human gastric cancer cells were injected intraperitoneally (IP) in severe combined immunodeficient mice. Mice were treated with NDV(F3aa)-GFP either once or multiple times after tumor challenge. Effective killing of MKN-74 cells by NDV(F3aa)-GFP was found in vitro. This cancer killing was dose-related and correlated with viral replication. GFP expression was a good marker of infection. The virus was also effective as an antitumor therapy in a peritoneal cancer model that simulates clinical disease. Half the animals treated with virus had no evidence of disease. Genetically engineered NDV [NDV(F3aa)-GFP] administered IP is an effective antitumor therapy against peritoneal carcinomatosis from human gastric cancer in a xenograft model, without significant toxicity. These data provide further rationale for clinical trials involving NDV for peritoneal carcinomatosis from gastric cancer.
authors.affiliation: Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
authors.forename: Kyo Young
authors.initials: KY
authors.lastname: Song
authors.forename: Joyce
authors.initials: J
authors.lastname: Wong
authors.forename: Lorena
authors.initials: L
authors.lastname: Gonzalez
authors.forename: Gang
authors.initials: G
authors.lastname: Sheng
authors.forename: Dmitriy
authors.initials: D
authors.lastname: Zamarin
authors.forename: Yuman
authors.initials: Y
authors.lastname: Fong
mesh_terms: D000818:Animals; D045744:Cell Line, Tumor; D005260:Female; D049452:Green Fluorescent Proteins / Q000235:genetics; D006801:Humans; D051379:Mice; D008810:Mice, Inbred C57BL; D016513:Mice, SCID; D009368:Neoplasm Transplantation; D009522:Newcastle disease virus / Q000235:genetics*; D050130:Oncolytic Virotherapy / Q000379:methods*; D010534:Peritoneal Neoplasms / Q000473:pathology / Q000628:therapy; D010537:Peritoneum / Q000473:pathology*; D013274:Stomach Neoplasms / Q000473:pathology / Q000628:therapy
chemical_list: C485184:enhanced green fluorescent protein; D049452:Green Fluorescent Proteins
references.citation: Cancer Res. 1994 Dec 1;54(23):6017-21
references.pmid: 7954437
references.citation: Proc Natl Acad Sci U S A. 2006 May 23;103(21):8203-8
references.pmid: 16717196
references.citation: J Mol Med (Berl). 2000;78(3):166-74
references.pmid: 10868479
references.citation: J Natl Cancer Inst. 1994 Aug 17;86(16):1228-33
references.pmid: 8040891
references.citation: Lancet. 1971 Oct 9;2(7728):825
references.pmid: 4106650
references.citation: J Surg Oncol. 2008 Sep 15;98(4):273-6
references.pmid: 18726891
references.citation: J Virol. 2003 Sep;77(17):9522-32
references.pmid: 12915566
references.citation: Cancer. 1991 Jan 1;67(1 Suppl):260-5
references.pmid: 1984825
references.citation: Surg Oncol Clin N Am. 2002 Jul;11(3):661-80
references.pmid: 12487061
references.citation: Cancer Lett. 2001 Oct 22;172(1):27-36
references.pmid: 11595126
references.citation: Gan No Rinsho. 1986 Aug;32(10):1203-9
references.pmid: 2431172
references.citation: Cancer Res. 2007 Sep 1;67(17):8285-92
references.pmid: 17804743
references.citation: Gastric Cancer. 2002;5(1):1-5
references.pmid: 12021853
references.citation: Cancer Treat Res. 2007;134:195-214
references.pmid: 17633055
references.citation: Oncology. 2000 Feb;58(2):96-107
references.pmid: 10705236
references.citation: J Surg Res. 1992 May;52(5):448-53
references.pmid: 1619912
references.citation: Mol Med. 1998 Dec;4(12):783-94
references.pmid: 9990864
references.citation: Ann Oncol. 2004 Sep;15(9):1344-7
references.pmid: 15319239
references.citation: CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
references.pmid: 15761078
references.citation: J Virol. 2006 Jun;80(11):5145-55
references.pmid: 16698995
references.citation: Cancer Res. 2002 Nov 1;62(21):6070-9
references.pmid: 12414631
references.citation: Med Oncol Tumor Pharmacother. 1992;9(4):169-71
references.pmid: 1342060
references.citation: J Virol. 1994 Nov;68(11):7654-8
references.pmid: 7933158
references.citation: J Gastroenterol. 2008;43(4):256-64
references.pmid: 18458840
references.citation: Eur J Surg Oncol. 2008 Jan;34(1):36-41
references.pmid: 17442532
references.citation: J Natl Cancer Inst. 1999 Oct 20;91(20):1708-10
references.pmid: 10528013
references.citation: Oncology (Williston Park). 2002 Nov;16(11):1483-92; discussion 1495-7
references.pmid: 12469927